Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report)'s stock price hit a new 52-week low during trading on Saturday after Truist Financial lowered their price target on the stock from $26.00 to $19.00. Truist Financial currently has a hold rating on the stock. Integra LifeSciences traded as low as $15.95 and last traded at $16.99, with a volume of 659615 shares traded. The stock had previously closed at $17.42.
Separately, Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Integra LifeSciences presently has a consensus rating of "Hold" and a consensus price target of $22.71.
View Our Latest Research Report on IART
Institutional Trading of Integra LifeSciences
Institutional investors and hedge funds have recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership increased its stake in Integra LifeSciences by 7.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after purchasing an additional 913 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Integra LifeSciences by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after acquiring an additional 1,437 shares during the period. Sterling Capital Management LLC lifted its holdings in Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after acquiring an additional 1,931 shares during the last quarter. Finally, Covestor Ltd boosted its stake in Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after acquiring an additional 2,071 shares during the period. Institutional investors and hedge funds own 84.78% of the company's stock.
Integra LifeSciences Price Performance
The company has a market capitalization of $1.24 billion, a P/E ratio of -178.65, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The company has a fifty day moving average price of $22.08 and a 200 day moving average price of $22.34.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to analysts' expectations of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm's quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the business posted $0.89 earnings per share. On average, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.
About Integra LifeSciences
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
See Also
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
